Cubist Systematic Strategies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Cubist Systematic Strategies’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,000	Closed	-$42K	–	4800
2022 Q3	$42K	Sell	18,000 -2,975	-14%	-$10.5K	﹤0.01%	4155
2022 Q2	$64K	Buy	20,975 +8,484	+68%	+$41.3K	﹤0.01%	4056
2022 Q1	$85K	Buy	12,491 +5,294	+74%	+$37.7K	﹤0.01%	3282
2021 Q4	$60K	Sell	7,197 -4,380	-38%	-$36.1K	﹤0.01%	3285
2021 Q3	$86K	Sell	11,577 -19,555	-63%	-$121K	﹤0.01%	2769
2021 Q2	$212K	Buy	31,132 +3,279	+12%	+$27.2K	﹤0.01%	2521
2021 Q1	$286K	Buy	+27,853	New	+$305K	﹤0.01%	2282
2020 Q4	–	Sell	-54,172	Closed	-$442K	–	2765
2020 Q3	$442K	Buy	+54,172	New	+$336K	0.01%	1820
2020 Q1	–	Sell	-2,793	Closed	-$24K	–	2558
2019 Q4	$24K	Buy	+2,793	New	+$15.1K	﹤0.01%	2334
2018 Q2	–	Sell	-10,863	Closed	-$243K	–	2127
2018 Q1	$243K	Buy	+10,863	New	+$241K	0.01%	1278

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cubist Systematic Strategies's JNCE Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 18,000 shares — an estimated $42K sold.

Cubist Systematic Strategies first reported a position in JNCE in Q1 2018 and held it in 10 quarters. The position peaked at $442K in Q3 2020. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Cubist Systematic Strategies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 18,000 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $42K.
Cubist Systematic Strategies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 10 quarters.
Cubist Systematic Strategies's Jounce Therapeutics, Inc. Common Stock position peaked at $442K in Q3 2020.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.